Radiomics
Insight-based
decision making

Diseases and
therapeutic areas

Industry
and Pharma

Healthcare
professionals

Scientific
researchers

About Radiomics


Radiomics is a next generation Liege-based imaging research organization built upon the unparallel experience of its founders, pioneers of the radiomics science.
 
Radiomics focuses on AI powered healthcare, with a unique expertise in Radiomics, Deep Learning & Federated Learning applied to oncology and other therapeutic areas. Through our proprietary advanced image analysis technology, we aim to unravel the gold mine of hidden data information embedded in standard medical images.
 
Our final goal is to support insight-based decision making for optimizing pharmaceutical and biotech companies’ clinical trials and drug development studies and for providing clinicians with a patient-centered approach based on personalized medicine. With this aim, Radiomics’ R&D team is continuously working on new solutions, in collaboration with multiple national and international partners.

We can help you

optimize

Optimize

Your clinical trials (in terms of costs and time)

detect

Detect

The subtlest signals of drugs efficacy and safety risk
facilitate

Facilitate

Your crucial
go / no-go
decisions
identify

Identify

Patients likely to respond to your treatment
strenghten

Strengthen

Your points
in pay for outcome scenarios

Why Radiomics

Experience

Our scientists and clinicians are the ones who invented radiomics and have unparalleled experience and international recognition in this AI field.

Outreach

Radiomics has clients and partners in the EU, the US, Africa and Australia. Permanent presence in North America and China are in our plans for the near future.

IP Portfolio

Radiomics' comprehensive IP portfolio includes both granted and pending international (EU/US) patents.

People

Radiomics' team is composed of a multicultural and multidisciplinary set of people, specialized in a broad range of domains always enthusiastic in addressing clients and partner's needs. 

Publications

Radiomics has numerous publications in high impact journals such as Nature Reviews, Clinical Oncology, Annals of Oncology and many more. 

Latest news

press
  • November 25th, 2021

Radiomics announces the strategic support of OncoDNA in its prospective clinical trial SALMON


The two Belgian companies will work towards a better understanding of non-small cell lung cancer biology and characterization of the tumors using of AI technology

press
  • November 17th, 2021

Radiomics secures €6 Million to fund new projects and initiatives


Radiomics announced that it has secured €6 Million in a pre-series B funding led by its main investors (Epimede and Noshaq) and backed by its original funders, its management team, some banks and non-dilutive financing from Walloon Regional Authorities in support of R&D Projects.

press
  • November 9th, 2021

Kazia Therapeutics and Radiomics collaborate in development of novel therapy


Radiomics, AI-powered imaging research organization, and Kazia Therapeutics, Australian oncology company developing innovative, high-impact drugs for cancer, announced that they have entered into a partnership to enhance imaging insights for the clinical development of EVT801.